u/BlackberryThese4801

​

so my doctor wanted me off it for a few weeks before some routine bloodwork because she wanted to see my baseline numbers without the medication affecting them. fine, valid, whatever. nobody warned me that without reta my hunger would come back like it had six months of catching up to do. I have eaten things I am not proud of. I genuinely forgot how exhausting it was to think about food this much and now I'm back in it and I hate it here. getting back on next week and I have never looked forward to a shot more in my life

so i started reta about two weeks ago at 1mg and i genuinely feel zero difference. no appetite suppression, no nausea, none of the stuff people usually describe in the first couple weeks. not complaining about the lack of side effects obviously but i also want to know something is actually happening. at what point is it reasonable to move up to 2mg or 2.5mg and has anyone else started this low and just felt nothing for a while or should i already be feeling something by now

​

Star sem 27 let in ko hodim po stopnicah mi pokajo oz. škripajo kolenski sklep in gležnji. Je to nevarno? Nič me ne boli.

​

I'm not a cardiologist, so much of it flew over my head, but I managed to find some media coverage for two new trials presented during the cardiology conference last week, and I think they're definitely worth mentioning.

In the first trial, researchers examined the outcomes of people with type 2 diabetes undergoing PCI, which is essentially an angioplasty procedure designed to reopen blocked coronary arteries. Using real-world data, they compared the incidence of deaths and cardiovascular events between patients taking tirzepatide and dulaglutide (Trulicity), respectively. The results showed that patients receiving tirzepatide had a significantly reduced risk of death within one year, by 62%, and major cardiovascular events, by 54%. In the second trial, researchers focused on the safety profile of people with obesity undergoing TAVR, which is yet another cardiovascular surgery procedure. Patients not on tirzepatide had a significantly increased risk of adverse events, by 44%, and heart failure hospitalizations, by 54%.

However, since these studies are not controlled experiments but observational studies, this must be taken into account. In observational studies, causation cannot be established; associations can only be found between the factors studied. However, the effect size is quite substantial, and the results are supported by other real-world evidence. The death of my father due to a heart attack at age 62 makes such information especially memorable for me. This is why I continue taking these drugs despite the unchanging reading on the scales. Losing weight is wonderful, yet protecting myself from a heart attack could save my life someday.